poradic primary hyperparathyroidism is the most common cause of hypercalcemia in the outpatient population, with a prevalence of one per 500 women and one per 2000 men over 40 years of age. Both increased cell proliferative activity and a decreased sensitivity of cells to secretory inhibition by calcium occur in hyperparathyroidism (1). The diagnosis of hyperparathyroidism is usually made by the demonstration of an inappropriately elevated parathyroid hormone level compared to the simultaneously measured serum calcium level (2). In 80% to 85% of patients, primary hyperparathyroidism is caused by one or more parathyroid adenomas, and in 15% to 20% of cases, it is the result of parathyroid hyperplasia. A rare cause of primary hyperparathyroidism, accounting for less than 1% of all cases, is parathyroid carcinoma. Persistent hyperparathyroidism occurs in 5% to 10% of all patients who undergo surgery for primary hyperparathyroidism, with a continuation of the pre-operative hypercalcemia in the immediate post-operative period. Hyperparathyroidism that presents after a period of more than six months of normocalcemia following surgery is called "recurrent hyperparathyroidism" and is commonly due to continuing growth of the remaining parathyroid glands (3). Secondary hyperparathyroidism is a compensatory hypertrophy of all parathyroid glands due to hypocalcemia, as occurs in renal failure or with vitamin D deficiency (4), whereas tertiary hyperparathyroidism describes the development of autonomous function of parathyroid tissue after longstanding secondary hyperparathyroidism (5-8).
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In most cases (80%-85%), parathyroid adenomas are found adjacent to the thyroid gland, which is the normal location for these adenomas. However, in up to 20% of cases, they are ectopically placed, e.g., in the anterosuperior, posterosuperior, or very rarely in the mid-lower mediastinum. Occasionally, parathyroid adenomas may be found within, or lateral to, the carotid sheath. Rarely, the lower parathyroid glands fail to migrate, remaining in the high neck anterior to the carotid bifurcation. Finally, 1.4% to 3.2% of all parathyroid adenomas are intrathyroidal, i.e., embedded completely within the thyroid gland (9) .
Among the several imaging procedures that have been developed for the detection and localization of parathyroid adenomas, dual-phase scintigraphy with Tc-99m sestamibi combined with ultrasonography is considered the imaging method of choice for pre-operatively localizing parathyroid adenomas. The overall accuracy of dual-phase scintigraphy combined with ultrasonography has been found to be superior to that of other scintigraphic or radiological techniques (10, 11) . Studies comparing planar imaging and single photon emission computed tomography (SPECT) have shown significantly increased sensitivity for Tc-99m sestamibi SPECT, thus supporting its routine use prior to surgery (12) (13) (14) .
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ORIGINAL ARTICLE Accuracy of parathyroid imaging: a comparison of planar scintigraphy, SPECT, SPECT-CT, and C-11 methionine PET for the detection of parathyroid adenomas and glandular hyperplasia Mehmet Özer Öksüz, Helmut Dittmann, Corinna Wicke, Karsten Müssig, Roland Bares, Christina Pfannenberg, Susanne Martina Eschmann PURPOSE To compare the accuracy of planar scintigraphy, single photon emission computed tomography (SPECT), SPECT-CT, and positron emission tomography (PET) with C-11 methionine for the pre-operative detection of parathyroid adenomas.
MATERIALS AND METHODS
We retrospectively evaluated the pre-operative studies of 60 patients with primary (n=56) and secondary (n=4) hyperparathyroidism. In 25/60 patients (Group 1), only planar scans were obtained, and additional SPECT and SPECT-CT were carried out in 35/60 patients (Group 2). PET or PET-CT with C-11 methionine was conducted in 8/60 patients (Group 3).
RESULTS
The results of the planar scans (Group 1) were true positive in 19/25 patients and false negative in 6/25 patients (sensitivity per patient, 76%). Histopathology confirmed 27 adenomas and two hyperplasia. Planar imaging identified 20/29 of these pathologies, whereas 9/29 were missed (sensitivity per adenoma, 69%). SPECT (Group 2) results were true positive in 34/35 patients and false negative in only one case (sensitivity per patient, 97%). On a lesion-based analysis, 38 adenomas were identified, and two were missed (sensitivity per adenoma, 95%). The sensitivities of SPECT and SPECT-CT were equal; however, SPECT-CT provided superior topographic information. C-11 methionine PET (Group 3) results were true positive in all eight patients. In one case, surgery confirmed two ipsilateral adenomas, only one of which was identified by PET (sensitivity per patient, 100%; per adenoma, 88.9%).
CONCLUSION
SPECT is superior to planar imaging. SPECT-CT has identical sensitivity compared to SPECT alone, but it provides additional topographic information. The sensitivity of PET appears to be even higher compared to SPECT. In the case of negative scintigraphic findings and proven hyperparathyroidism, additional C-11 methionine PET or PET-CT is recommended.
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Diagn Interv Radiol 2011; 17:297-307 performed with 7.5-to 10-MHz transducers. Parathyroid adenomas were identified as hypoechoic nodules with well-defined margins that were mostly localized outside the thyroid gland.
Planar scintigraphy
Anterior planar views of the neck and thorax (10 min/frame; matrix size, 256×256) were acquired with the patients in the supine position. Images were obtained at 10 min (thyroid phase) and 120-150 min (parathyroid phase) after intravenous injection of 400 MBq (10.81 mCi) Tc-99m sestamibi using a large field-of-view gamma camera equipped with a high-resolution collimator.
SPECT and SPECT-CT
SPECT-CT imaging of the neck and thorax was carried out immediately after the planar imaging using a dualhead variable-angle gamma camera with a low-power X-ray CT transmission system mounted on the same gantry (Millennium VG Hawkeye, GE Medical Systems, Carrollton, Texas, USA). The transmission data were reconstructed using filtered back-projection to produce cross-sectional attenuation images in which each pixel represents the estimated X-ray attenuation of the imaged tissue. The SPECT component of the study was then obtained in 120 projections, with a 3° angle step, in a 128×128 matrix, and at 20 s per view. Reconstruction was performed iteratively using the ordered subsets expectation maximization technique (OSEM). The emission images, obtained in transaxial, sagittal, and coronal planes, were inherently registered to the anatomic maps using eNTEGRA workstation software (GE Medical Systems) followed by the generation of hybrid images of the superimposed transmission (CT) and emission (SPECT) data.
Thyroid scintigraphy
Seven patients in Group 1 and nine patients in Group 2 with concomitant thyroid nodules also obtained a planar thyroid scan following the administration of 75 MBq (2.03 mCi) of Tc-99m pertechnetate for comparison with earlier parathyroid images.
PET and PET-CT
In four patients, PET was performed with a dedicated PET scanner (Advance, GE Medical Systems, Milwaukee, Wisconsin, USA). Fifteen minutes after the intravenous injection of 700 MBq (18.92 mCi) of C-11 methionine, two contiguous 15-min emission scans were performed of the neck and upper mediastinum followed by two 10-min transmission scans for the attenuation correction using a Ge-68 source.
Four patients underwent imaging with a dedicated PET-CT system (Biograph 16 HiRez, Siemens Medical Solutions, Erlangen, Germany) 15 min after the intravenous injection of 700 MBq (18.92 mCi) of C-11 methionine. Images of the neck and thorax, from the base of the skull to the diaphragm, were obtained in three consecutive bed positions, each of which was 5 min in duration. For attenuation correction, a non-contrast CT scan was performed first and was followed by a contrast-enhanced CT protocol (Ultravist 370, Schering, Berlin, Germany).
Image interpretation
The datasets of planar scintigraphy, SPECT and SPECT-CT, PET and PET-CT were interpreted visually by a team of three nuclear medicine physicians and two radiologists. In cases of questionable findings, the decision was made by consensus of at least two observers. A distinct focus of increased uptake within or neighboring the thyroid in the mediastinum on either an early or a late image, or both, was considered positive for abnormal parathyroid tissue, unless it could be attributed to a thyroid nodule using the pertechnetate scan. The SPECT-CT and PET-CT images were analyzed for adenoma localization in relation to adjacent anatomic structures. The final diagnosis of a parathyroid adIn this study, we compared the accuracies of planar scintigraphy, SPECT, SPECT-CT with Tc-99m sestamibi and positron emission tomography (PET) with C-11 methionine for the detection of parathyroid adenomas and/or hyperplasia.
Materials and methods

Patients
A total of 60 patients (44 females, 16 males) with a mean age of 51±29 years (range, 22-80 years) with biochemical evidence of hyperparathyroidism, i.e., increased serum calcium and parathyroid hormone concentrations, that were scheduled for surgery were evaluated. Fifty-six patients had primary hyperparathyroidism, and four had secondary hyperparathyroidism. One case of primary hyperparathyroidism was associated with multiple endocrine neoplasia type 1 (MEN 1).
All patients underwent ultrasound of the neck and parathyroid scintigraphy with Tc-99m sestamibi. Patients with concomitant thyroid disease received an additional thyroid scan with Tc99m pertechnetate.
In 25 patients, only planar scans with Tc-99m sestamibi were obtained (Group 1) ( Table 1) . In 35 patients, additional SPECT and SPECT-CT was carried out (Group 2) ( Table 1) . PET (4 patients) or PET-CT (4 patients) with C-11 methionine was performed in 8 of the 60 patients (Group 3) ( Table 1) .
The local ethics committee approved the study, and written informed consent was obtained from all patients before they were enrolled in the study.
Ultrasonography
In all patients, a pre-operative highresolution ultrasound of the thyroid gland and surrounding tissues was For 25 patients (Group 1), only planar scans were obtained, and in 35 patients (Group 2), additional SPECT and SPECT-CT was carried out. a PET or PET-CT with C-11 methionine was carried out in 8 patients (Group 3, 4x PET and 4x PET-CT).
enoma, whether cervical or ectopic, was based on the intraoperative and pathologic findings.
Data analysis
Planar scintigraphy, SPECT and SPECT-CT studies for all patients; PET studies for four patients; and PET-CT studies for four patients were retrospectively analyzed. This was followed by an assessment of the detectability rate and the sensitivity of these modalities, as defined by surgical findings and histopathologic confirmation. SPECT or SPECT-CT was considered to be helpful in image interpretation if it provided precise localization with respect to the depth of the suspected lesion and its relation to adjacent structures including the thyroid gland, trachea, esophagus, thymus, spine, and sternum. The chi-square test and the Wilcoxon test were used for statistical analysis of the sensitivities.
Surgery and histopathology
All patients underwent surgical exploration. The appearance, size, and location of every parathyroid gland were documented. Histopathologic examination was performed, and weights and volumes of all resected specimens were obtained.
Results
Parathyroidectomy was performed in all 60 patients after parathyroid imaging revealed 63 parathyroid adenomas and six hyperplastic parathyroid glands.
Group 1 (planar imaging)
The results of the planar scans were true-positive in 19/25 patients and false-negative in 6/25 patients. Histopathology confirmed 27 adenomas and two cases of hyperplasia, i.e., one patient with secondary hyperparathyroidism and one patient with MEN 1 who had a hyperplastic parathyroid gland and a contralateral adenoma. Twenty adenomas and two hyperplastic parathyroid glands were identified by planar imaging, whereas nine adenomas were missed. This leads to a sensitivity per patient of 76% and per adenoma of 69% (Table 2 ). In two patients, only one of two adenomas was detected. In both cases, the contralateral smallersized adenoma was missed. In three patients, the detected adenomas were placed ectopically in the anterosuperior mediastinum (Table 3) .
Group 2 (SPECT and SPECT-CT)
The SPECT images were true-positive in 34/35 patients ( Fig. 1 ) and false-negative in only one case. In one patient, only one of two adenomas was identified. In another patient, SPECT images revealed two foci, whereas surgery and histopathology confirmed only one adenoma and a contralateral thyroid nodule. The lesion-based analysis revealed that 38 adenomas were identified with SPECT, and only two parathyroid adenomas were missed. In four cases, histology revealed hyperplastic parathyroids, and all were true-positives. This leads to a sensitivity per patient of 97% and per adenoma of 95% (Table 2) .
In five patients, six abnormal parathyroid glands were found in ectopic locations. One patient had one adenoma and one hyperplastic parathyroid gland in the anterosuperior mediastinum. Another patient had one adenoma in the anterosuperior mediastinum and one adenoma in an anatomically correct position, i.e., posterior to the lower pole of the right thyroid lobe. In one case, the adenoma was located in the mid-lower mediastinum in proximity to the left main bronchus (Figs. 2 and  3) , and in the next patient, the parathyroid adenoma was located in the posterosuperior mediastinum near the aortic arch/descending aorta. Finally, in one patient, the atypical adenoma was embedded within the lower pole of the left thyroid gland, i.e., an intrathyroidal parathyroid adenoma ( Table 3) .
The sensitivities of SPECT and SPECT-CT were equal. However, SPECT-CT provided superior topographic information, particularly in those patients with ectopic localization of parathyroid adenomas (Fig. 3) .
Group 3 (PET and PET-CT)
C-11 methionine-PET images were true-positive in all eight patients (Fig.  4) . In one case, surgery confirmed two ipsilateral adenomas, only one of which was identified by PET (sensitivity per patient of 100% and per adenoma of 88.9%).
In Group 1 (planar imaging) and Group 2 (SPECT and SPECT-CT), the size of the parathyroid glands showed a wide range from relatively small to fairly large volumes of 0.01 mL up to 4.41 mL (Fig. 5, Tables 4 and 5 ). Adenomas that were missed were generally smaller than the majority of all parathyroid adenomas (statistically significant in Group 1 with [P = 0.014] and without [P = 0.027] the two large true-positive adenomas based on the Wilcoxon test). 
Discussion
Contemporary modalities that help endocrine surgeons localize abnormal parathyroid glands in patients with hyperparathyroidism provide highresolution anatomical and functional images of hyperactive endocrine tissue. When used in tandem, neck ultrasound and Tc-99m sestamibi parathyroid scintigraphy using various imaging techniques (subtraction or dual-phase imaging) have been shown to be effective in localizing adenomas to allow pre-operative planning and intra-operative decision making (15) (16) (17) (18) (19) (20) .
Focused neck exploration in patients with primary hyperparathyroidism has recently replaced the traditional bilateral approach due to a decrease in operative morbidity and a shortening Planar scintigraphy has been considered the primary imaging modality for the pre-operative localization of parathyroid adenomas with pooled sensitivities of 87% for subtraction imaging and 73% for dual-phase imaging (23) . The results of the present study (Group 1) revealed sensitivities of 76% on patient-based and 69% on lesion-based analysis and are within the range of the results from the dual-phase methods reported in the literature (24) .
Our study comparing planar imaging and SPECT supports the wide application of SPECT, which has increased sensitivities compared to planar scintigraphy of 97% on patient-based and 95% on lesion-based analysis. These values are similar to previously published data with sensitivities ranging from 92% to 96 % (25) (26) (27) (28) (29) .
In the present study, the patientand lesion-based sensitivities of SPECT and SPECT-CT were equal for the detection rate of parathyroid adenomas. However, SPECT-CT provided superior topographic information, particularly in those patients with an ectopic localization of parathyroid adenomas, facilitating a surgical approach by providing anatomic mapping prior to exploration (30) .
Gland volume (weight) and gland vascularity are known to have an influence on radionuclide uptake. They probably correlate with an increased delivery and, consequently, with an increased accumulation of radiotracer in an abnormal parathyroid gland (31) . Planar imaging (Group 1) identified 20/29 parathyroid adenomas (69%) with volumes ranging from 0.29 mL to 3.91 mL but missed 9/29 adenomas with gland volumes of 0.16 mL to 1.2 mL, whereas SPECT and SPECT-CT (Group 2) were able to detect 38/40 adenomas (95%) with volumes between 0.01 mL and 4.41 mL (Fig. 5) . Two small adenomas (0.3 and 0.36 mL) were missed. These findings illustrate that the increased sensitivity of SPECT and SPECT-CT compared to planar scintigraphy can be attributed to a higher detection rate of particularly small adenomas due to a superior contrast resolution, depth information and accurate three-dimensional localization.
Histopathology of the two falsenegative findings of Group 2 (SPECT and SPECT-CT) revealed that one of the missed adenomas was characterized by only a few adenoma-like cells corresponding to a low functional status. In the other case, one of two adenomas was correctly depicted, but the missed adenoma showed a fairly low content of oxyphil cells. As previously reported, the presence of oxyphil cells that are rich in mitochondria is essential for radionuclide retention (32) .
It has been reported in the literature that parathyroid scintigraphy with Tc-99m sestamibi is less sensitive in the detection of hyperplastic parathyroid glands compared to parathyroid adenomas (33, 34) . However, in our study, all false-negative cases occurred in patients with primary hyperparathyroidism with histopathologically small parathyroid adenomas. The six hyperplastic parathyroid glands, two in Group 1 (secondary hyperparathyroidism, MEN 1) and four in Group 2 (secondary hyperparathyroidism in three cases, primary hyperparathyroidism in one case) were correctly detected.
Although 80% to 85% of parathyroid adenomas are found adjacent to the thyroid gland in their normal position, up to 20% are located at ectopic sites. The term "major ectopy" refers to parathyroid adenomas located in the mediastinum; high in the neck, Figure 5 . Gland volumes of detected (true positive) and non-detected (false negative) enlarged parathyroid glands (adenoma, hyperplastic gland). The increased sensitivity of SPECT and SPECT-CT (Group 2) compared to planar scintigraphy (Group 1) can be attributed to a higher detection rate of particularly small adenomas due to a superior contrast resolution, depth information and accurate threedimensional localization. Figure 6 . Imaging algorithm for patients with proven hyperparathyroidism. Dual-phase Tc-99m sestamibi SPECT-CT in combination with ultrasonography imaging is the method of choice to localize parathyroid adenomas and/or hyperplasia. If thyroid nodules are found on ultrasonography, thyroid scintigraphy should be performed. In the case of negative scintigraphic findings, C-11 methionine PET or PET-CT should be performed. in, or lateral to, the cervical neurovascular bundle; or within the thyroid gland (35) . In our study, we found ectopic adenomas in 9 out of 60 patients (15%), which is comparable to figures reported in the literature (8% to 20%) (36) (37) (38) . Most of the ectopic adenomas (6/9) were localized in the anterior superior mediastinum. One patient had an ectopically located parathyroid adenoma in the mid-lower mediastinum on the ventral aspect of the left main bronchus (Figs. 2 and 3) , and in another patient, the parathyroid adenoma was located in the posterior superior mediastinum near the aortic arch/descending aorta.
As a rare cause of primary hyperparathyroidism, we found an intrathyroidal parathyroid adenoma within the lower pole of the thyroid gland. Based on the known embryology, it was originally thought that intrathyroidal adenomas would involve only the superior parathyroid glands (39, 40) . However, data available from more recent reviews have shown that intrathyroidal parathyroid adenomas or hyperplastic glands may involve either the superior or inferior glands (41) (42) (43) .
One patient in our study had two anomalous parathyroid glands, i.e., one adenoma and one hyperplastic parathyroid gland, and both were ectopically located in the anterior superior mediastinum. Current evidence regarding the histopathogenesis of parathyroid adenoma and hyperplasia is unclear. Although most adenomas are monoclonal proliferations, suggesting a neoplastic origin, histopathologic evidence indicates the evolution to a monoclonal adenoma from polyclonal hyperplasia and vice versa (44) (45) (46) . Therefore, parathyroid adenoma and hyperplasia could be the same disease entity, representing opposite ends of the spectrum of phenotypic expression. The prevalence of hyperplasia varies considerably in different studies, and there appears to be a strong influ- Single adenomas and parathyroid cancer have also been described in the setting of MEN 1 (49, 50) . One patient in our study with MEN 1 had an adenoma posterior to the superior pole of the right thyroid lobe and a hyperplastic parathyroid gland posterior to the inferior pole of the contralateral thyroid lobe.
It is known that tracer accumulation and retention is not limited to the presence of a parathyroid adenoma or hyperplasia. Less than 1% of parathyroid carcinomas are the culprit of positive imaging findings, and in some cases a thyroid nodule is the reason for false-positive findings, as was the case for one patient of Group 2 in our study (51) .
PET and PET-CT with C-11 methionine is an alternative imaging technique to identify hyperfunctioning parathyroid tissues in primary, secondary and recurrent or persistent hyperparathyroidism. PET offers advantages over SPECT; in particular, PET has superior spatial resolution. The high sensitivity of C-11 methionine may also be explained by characteristics in the intermediary metabolism such as transmembrane amino acid transport, protein synthesis and methionine donor transmethylation. Although the number of cases studied to date with C-11 methionine PET is still small, its efficacy in localizing hyperfunctioning glands in hyperparathyroidism appears to be superior to that of Tc-99m sestamibi (52) (53) (54) (55) .
The sensitivity in the presented cases of eight patients (Group 3, sensitivity per patient: 100%, sensitivity per adenoma: 88.9%) is comparable to those previously published (56) . Rubello et al. (57) stated that size may not be the best determinant of dysfunction of parathyroid glands and concluded that C-11 methionine PET may provide additional information in the evaluation of patients with negative or equivocal findings on parathyroid scans.
The most significant limitation of our study was the small number of patients receiving C-11 methionine PET or PET-CT. Further clinical trials with larger patient populations for a reliable statistical analysis are needed to prove the superiority of C-11 methionine PET or PET-CT, particularly in cases of negative Tc-99m sestamibi SPECT examinations.
In conclusion, for the detection of parathyroid adenomas, SPECT is clearly superior to planar imaging. SPECT-CT has identical sensitivity compared to SPECT alone, but it provides additional topographic information that is relevant for subsequent surgery, particularly in cases of ectopic glands. Thus, parathyroid SPECT-CT is highly accurate for the localization of parathyroid adenomas. The sensitivity of PET appears to be even higher compared to that of SPECT, although the number of patients in this study is too small for statistical analysis. In the case of negative scintigraphic findings and proven hyperparathyroidism, additional C-11 methionine PET or PET-CT should be performed (Fig. 6 ).
